P3 Prostate Cancer Forum: 17th - 18th May, 2024

perspectives, possibilities, progress

The landscape of prostate cancer treatment is rapidly evolving. The P3 Forum is dedicated to offering education and diverse expert perspectives on the latest advancements in the field, providing in-depth insights into the treatment and care of patients with advanced prostate cancer.

The expert P3 panel shares valuable insights on how to effectively leverage the latest treatments to extend survival and importantly, maintain quality of life. They explore the impact of new screening protocols and next generation imaging on prostate cancer detection, staging, and treatment, and investigate the latest guidelines and how they impact clinical practice.

Featuring short videos, discussions on patient case studies, and interactive Q&A sessions, enhance your professional development now through a 4-stage prostate cancer journey.

These promotional meetings have been initiated and funded by Bayer UK and are for UK Healthcare professionals only.

Start here with an introduction from Professor Amit Bahl: Navigating the Prostate Cancer Treatment Landscape

NUBEQA (darolutamide) Prescribing Information

Xofigo

^▼ (radium-223 dichloride) Prescribing Information

P3 Prostate Cancer Forum Session 1 & 2

Session 1: Prostate Cancer Screening: Current Perspective

Explore valuable insights on prostate cancer screening. Our expert panel delve into the changing dynamics.

PP-NUB-GB-2013, January 2025

Session 2: Decoding mHSPC: Unravelling the complexities

Our experts share their insights on optimising treatment in mHSPC, delving specifically into triple therapy.

PP-NUB-GB-2016, January 2025

P3 Prostate Cancer Forum Session 3 & 4

Session 3: Mapping the Journey: Strategies and RWE in nmC...

We gained insights into nmCRPC patients in the UK, and discussed how the treatment paradigm is shifting.

PP-NUB-GB-2017, January 2025

Session 4: Confronting the challenges of mCRPC

we took a deep dive into mCRPC; the latest therapies, data and key considerations for treatment sequencing.

PP-NUB-GB-2019, January 2025

CO-CHAIRS

Professor Philip Cornford
Professor Philip Cornford
Honorary Associate Professor
Liverpool University Hospitals NHS Foundation Trust
Chair of EAU Prostate Cancer Guidelines Panel
Professor Heather Payne
Professor Heather Payne
Honorary Consultant Clinical Oncologist
University College Hospital, London
Clinical Director of the Prostate Centre, London

SPEAKERS

Professor Alison Birtle
Professor Alison Birtle
Consultant Clinical Oncologist
MAHSC Honorary Clinical Professor in the Faculty of Biology, Medicine & Health at the University of Manchester, and Honorary Clinical Professor at The University of Central Lancashire
Professor Caroline Moore
Professor Caroline Moore
Professor of Urology at University College London in the Department of Targeted Intervention
Dr Matthew Hobbs
Dr Matthew Hobbs
Director of Research, Prostate Cancer UK
Dr Masood Moghul
Dr Masood Moghul
Post-CCT Urologist, PhD Student Royal Marsden Hospital and Institute of Cancer Research
Dr Alison Tree
Dr Alison Tree
Consultant clinical oncologist at The Royal Marsden
Dr Mark Linch
Dr Mark Linch
Consultant medical oncologist, Honorary senior lecturer at University College London (UCL) Cancer Institute
Dr Doraid Alrifai
Dr Doraid Alrifai
Consultant medical oncologist at St George’s University Hospital NHS Foundation Trust
Professor Andrew Protheroe
Professor Andrew Protheroe
Medical Oncologist within the University of Oxford department of Oncology at the Oxford Cancer and Haematology Centre
Dr Mark Prentice
Dr Mark Prentice
Consultant Clinical Oncologist Royal Free Hospital NHS Foundation Trust
Ms Fayiza Habeeb
Ms Fayiza Habeeb
Lead Nurse Practioner Royal Free Hospital London
Mr Bill Cross
Mr Bill Cross
Consultant Urologist Leeds Teaching Hospital Trust
Mr Asad Abedin
Mr Asad Abedin
Consultant Urological Surgeon at the Dudley Group NHS Foundation Trust
Ms Georgia Malesi
Ms Georgia Malesi
Principal Pharmacist for Cancer Services at the Dudley Group of Hospitals
Dr Mark Beresford
Dr Mark Beresford
Consultant Clinical Oncologist, Royal United Hospital Bath, Honorary Senior Lecturer at Bristol University, Visiting Researcher at Bath University
Dr Mike Osborn
Dr Mike Osborn
Clinical Psychologist, , Royal United Hospital Bath
Ms Paula Allchorne
Ms Paula Allchorne
Urology Lead Nurse Barts Health NHS Trust, Psychosexual Nurse Specialist and Relationship Therapist
Ms Vineetha Thankappan Nair
Ms Vineetha Thankappan Nair
Macmillan Lead Clinical Nurse Specialist
Mr Kieran O’Flynn
Mr Kieran O’Flynn
Consultant Urologist, Salford Royal Foundation Trust
Professor Robert Jones
Professor Robert Jones
Clinical Cancer Research at the University of Glasgow and a Consultant at the Beatson West of Scotland Cancer Centre
Dr Elena Castro
Dr Elena Castro
Consultant Medical Oncologist, Virgen de la Victoria University Hospital in Malaga, Spain

Are you interested in P3 2025?

PP-NUB-GB-2012 | January 2025